Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05131035

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk

This 10 week intervention, Specific Cognitive Remediation with Surround (or SCORES), is designed to target processing speed, a cognitive domain related directly to social functioning, which in turn, represents a vulnerability factor for psychosis. This remotely-delivered intervention combining targeted cognitive training exercises and group support was developed to directly impact processing speed, and at the same time, boost motivation and engagement in adolescents at risk for schizophrenia and other psychotic disorders.

Recruiting

Interested in participating?

Request Info

Key information

Age range

14 year–20 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Northwell Health- The Zucker Hillside Hospital

Glen Oaks, New York, 11042, United States

Location status: Recruiting

Location contact

Andrea M Auther, Ph.D.

CONTACT

[email protected]

718-470-8147

Barbara A Cornblatt, Ph.D.

PRINCIPAL_INVESTIGATOR

Danielle McLaughlin, M.A.

CONTACT

[email protected]

718-470-8375

Ricardo E Carrion, Ph.D.

PRINCIPAL_INVESTIGATOR

About this study

This study evaluates the effectiveness of a cognitive remediation (CR) program plus group coaching and support designed to improve processing speed and, in turn, social functioning and attenuated positive symptoms in individual considered Clinical High Risk for psychosis. The SCORES (Specific COgnitive REmediation with Support) intervention is a novel Cognitive Remediation program combined with group coaching, performance-based rewards, game-like tasks, and educational elements to increase engagement and retention. The study is funded by a R61/R33 award. In the R61 phase, all participants were asked to complete 40 hours of Cognitive Remediation or brain training (4 hours per week/10 weeks) with a mid-point assessment (at 5 weeks) to determine the training dose needed to impact processing speed as measured by the Matrics Cognitive Consensus Battery. The current R33 (Phase 2) will look to replicate the results of the R61 and assess the specificity of the targeted intervention with the addition of a non-speeded cognitive training group..

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meet Clinical High Risk (CHR) criteria on the Structured Interview for Psychosis Risk Syndromes, defined by the presence of at least one attenuated positive symptom at a moderate to severe level
  • A score representing 0.5 SD below the mean on Animal Naming, Trails A or BACS: Symbol Coding from the MATRICS Consensus Cognitive Battery (MCCB).

Exclusion criteria

  • Any DSM 5 Schizophrenia-Spectrum diagnosis
  • Non-English speaking
  • Past or current history of a clinically significant central nervous system disorder (e.g., seizure disorder)
  • Estimated IQ<70
  • Significant head injury
  • Significant substance abuse
  • Significant visual or auditory impairment.

Treatment and study plan

SCORES (Specific COgnitive Remediation with Support)

Behavioral

This study evaluates the effectiveness of a 10-week cognitive remediation program plus group coaching and therapy to improve processing speed and, in turn, social functioning and attenuated positive symptoms in CHR subjects. The SCORES (Specific COgnitive Remediation with Support) intervention is a novel CR program combined with group coaching, performance-based rewards, game-like tasks, and therapy elements to increase engagement and retention.

In the 2 year, R61 phase, all participants will complete 40 hours of CR (4 hrs per week) with a mid-point assessment (20 hours of CR at 5 weeks) to determine the impact of CR on processing speed as measured by the MCCB.

The second phase of the study (R33) will compare the 40 hours of speeded brain training to 40 hours of non-speeded brain training. This three year study will allow for a replication and assessment of specificity of the targeted intervention.

Primary outcomes

  1. Processing Speed domain score from the MATRICS Consensus Cognitive Battery (MCCB)

    Time frame: Baseline, Mid-Treatment (5 weeks), Post Treatment (10 weeks)

    Change in processing speed domain score and individual measures within the domain.

Secondary outcomes

  1. Global Functioning: Social (GF:Social) scale (Phase 2/R33 only)

    Time frame: Baseline, Mid-Treatment (5 weeks), Post Treatment (10 weeks)

    Change in GF:Social score from baseline to follow up timepoints. The GF:Social scale scores range from 1 to 10 with higher scores representing better social functioning.

  2. SIPS/SOPS: Positive Symptoms (Phase 2/R33 only)

    Time frame: Baseline, Mid-Treatment (5 weeks), Post Treatment (10 weeks)

    Change in Total Positive Symptom score from baseline to follow up timepoints. Each of the 5 positive symptoms on the SOPS range from 0-6 (6 indicating a psychotic symptom).

Study contacts

Contact information is provided by the study sponsor or research team.

Danielle McLaughlin, M.A.

CONTACT

[email protected]

718-470-8375

Ricardo E Carrion, Ph.D.

CONTACT

[email protected]

718-470-8788

Sponsors and collaborators

Lead sponsor

Northwell Health

Other

Collaborators

  • National Institute of Mental Health (NIMH)

Registry information

Official study title

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk in Adolescents at Clinical High Risk for Psychosis

Acronym: SCORES

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Nov 23, 2021
Registry last updated
Nov 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.